Wednesday, Urigen Pharmaceuticals Inc. (URGP.OB) appointed William Schmidt to its Scientific Advisory Board. Schmidt, a pharmacologist, has been a consultant to Urigen since 2006 assisting with development strategy for URG101. His experience includes the development of Combunox, a combination pain product and other pain products.
Urigen Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products for urological disorders. Its products include URG101, which completed Phase II clinical trial for the treatment of painful bladder syndrome/interstitial cystitis in men and women; and URG301, a proprietary dosage form of an approved drug, which targets a female urethral suppository for urethritis and nocturia.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.